We claim:

1. The compound of formula **I** and the pharmaceutically acceptable salts and tautomers thereof:



(I)

wherein:

R^1 is -$C_{1\text{-}6}$alkyl;

R^2 is -phenyl, unsubstituted, mono- or polysubstituted with a substituent selected from the group consisting of -halo, -$C_{1\text{-}6}$alkyl, -CF_3, -O-$C_{1\text{-}6}$alkyl, and -NO_2;

R^3 is selected from the group consisting of -H and -$C_{1\text{-}6}$alkyl;

R^4 is -$C_{1\text{-}6}$alkyl;

R^5 is -$C_{1\text{-}6}$alkyl;

R^6 is each independently selected from the group consisting of: -halo, -$C_{1\text{-}6}$alkyl, -CF_3, -O-$C_{1\text{-}6}$alkyl, and -NO_2; and

q is an integer from 0 to 4.

2. The compound of claim 1 and the pharmaceutically acceptable salts and tautomers thereof, wherein R^1 is -methyl.

3. The compound of claim 2 and the pharmaceutically acceptable salts and tautomers thereof, wherein R^2 is -phenyl, unsubstituted, mono- or polysubstituted with a substituent selected from the group consisting of: -halo, -$C_{1\text{-}6}$alkyl, -CF_3, and -O-$C_{1\text{-}6}$alkyl.

4. The compound of claim 3 and the pharmaceutically acceptable salts and tautomers thereof, wherein R^2 is selected from the group consisting of: -3-chlorophenyl, -4-chlorophenyl, -4-methoxyphenyl, -3-trifluoromethyl-phenyl, -4-trifluoromethyl-phenyl, -

3,4-dichlorophenyl, -3-bromophenyl, -4-bromophenyl and -3-trifluoromethyl-4-chlorophenyl.

5. The compound of claim 3 and the pharmaceutically acceptable salts and tautomers thereof, wherein R^3 is -H.

6. The compound of claim 4 and the pharmaceutically acceptable salts and tautomers thereof, wherein R^3 is -H.

7. The compound of claim 5 and the pharmaceutically acceptable salts and tautomers thereof, wherein R^4 is $-CH_3$.

8. The compound of claim 6 and the pharmaceutically acceptable salts and tautomers thereof, wherein R^4 is $-CH_3$.

9. The compound of claim 7 and the pharmaceutically acceptable salts and tautomers thereof, wherein R^5 is $-CH_3$.

10. The compound of claim 8 and the pharmaceutically acceptable salts and tautomers thereof, wherein R^5 is $-CH_3$.

11. The compound of claim 9 and the pharmaceutically acceptable salts and tautomers thereof, wherein R^6 is selected from the group consisting of $-CH_3$ and -halo.

12. The compound of claim 10 and the pharmaceutically acceptable salts and tautomers thereof, wherein R^6 is selected from the group consisting of $-CH_3$ and -halo.

13. The compound of claim 11 and the pharmaceutically acceptable salts and tautomers thereof, wherein q is 0 to 2.

14. The compound of claim 12 and the pharmaceutically acceptable salts and tautomers thereof, wherein q is 0 to 2.

15. The compound of claim 1, wherein said compound is selected from the group consisting of:

(1) Methyl-{1-[2-(1-phenyl-ethyl)-phenyl]-ethyl}-amine,
(2) Methyl-{1-[2-(1-phenyl-propyl)-phenyl]-ethyl}-amine,
(3) Dimethyl-{1-[2-(1-phenyl-ethyl)-phenyl]-ethyl}-amine,
(4) Methyl-{1-[2-(1-phenyl-ethyl)-phenyl]-propyl}-amine,
(5) (1-{2-[1-(3,4-Dichloro-phenyl)-ethyl]-phenyl}-ethyl)-methyl-amine,
(6) {1-[4,5-Dimethyl-2-(1-phenyl-ethyl)-phenyl]-ethyl}-methyl-amine,
(7) {1-[4,5-Dichloro-2-(1-phenyl-ethyl)-phenyl]-ethyl}-methyl-amine,
(8) (1-{2-[1-(4-Chloro-phenyl)-ethyl]-phenyl}-ethyl)-methyl-amine,
(9) (1-{2-[1-(3-Chloro-phenyl)-ethyl]-phenyl}-ethyl)-methyl-amine,
(10) (1-{2-[1-(4-Methoxy-phenyl)-ethyl]-phenyl}-ethyl)-methyl-amine,
(11) Methyl-(1-{2-[1-(4-trifluoromethyl-phenyl)-ethyl]-phenyl}-ethyl)-amine,
(12) Methyl-(1-{2-[1-(3-trifluoromethyl-phenyl)-ethyl]-phenyl}-ethyl)-amine,
(13) (1-{2-[1-(3,4-Dichloro-phenyl)-ethyl]-phenyl}-ethyl)-methyl-amine,
(14) (1-{2-[1-(4-Bromo-phenyl)-ethyl]-phenyl}-ethyl)-methyl-amine,
(15) (1-{2-[1-(3-Bromo-phenyl)-ethyl]-phenyl}-ethyl)-methyl-amine, and
(16) (1-{2-[1-(4-Bromo-3-trifluoromethyl-phenyl)-ethyl]-phenyl}-ethyl)-methyl amine,

and pharmaceutically acceptable salts and tautomers thereof.

16. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and as active ingredient the compound of formula I and pharmaceutically acceptable salts and tautomers thereof:



(I)

wherein:

R^1 is -C_{1-6}alkyl;

R^2 is -phenyl, unsubstituted, mono- or polysubstituted with a substituent selected from the group consisting of -halo, -C_{1-6}alkyl, -CF_3, -O-C_{1-6}alkyl, and -NO_2;

R^3 is selected from the group consisting of -H and -C_{1-6}alkyl;

R^4 is -C_{1-6}alkyl;

R^5 is -C_{1-6}alkyl;

R^6 is each independently selected from the group consisting of: -halo, -C_{1-6}alkyl, -CF_3, -O-C_{1-6}alkyl, and -NO_2; and

q is an integer from 0 to 4.

17. A method of treating depression in a patent, which method comprises administering to a patient a therapeutically effective amount of the compound of claim 1.

18. The method of claim 17, wherein said depression is selected from the group consisting of: unipolar depression, dysthymia, bipolar depression, treatment-resistant depression, and depression in the medically-ill.